For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

singup link button why should I sign up?
Clinical Protocol to Investigate the Efficacy of Amlexanox for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetes
Type 2 diabetes ( Type 2 diabetes mellitus ) Overweight ( Obesity )
Location of study visits: Ann Arbor, MI
The reason for this study is to find out how an investigational medicine, Amlexanox, can improve type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD).
This study is looking for: male   female  Both men and women
  • Volunteers with specific conditions
  • 18 years to 999 years
The reason for this study is to find out how an investigational medicine, Amlexanox, can improve type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD).
263 HEROES have already shown interest in this study. I am interested Print Study | Email Study
Who can participate?
What is involved? This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day. We plan to continue therapy for a period of 12 weeks followed by a follow-up 4 weeks after therapy ends. We will evaluate the changes in metabolic parameters (e.g. blood cholesterol, liver function, insulin resistance) and body composition characteristics (e.g. the pattern of fat distribution in the body). Seven eligible subjects in this study will also be evaluated for a change in liver disease by a liver biopsy.
Compensation $600-$9,999
We respect your privacy! UMClinicalStudies.org is a secure, password-protected database. All the information that you choose to share will be kept private and confidential. Read University of Michigan's Notice of Privacy Practices.